CLINICIANS

CartiONE Clinical Studies

CartiONE is a single surgery, Autologous Chondrocyte Implantation (ACI) procedure providing surgeons with a cell combination of the patient’s own freshly isolated cartilage and bone marrow cells. Results from Orteq’s original cell single-stage ACI procedure using the osteochondral Instruct Scaffold have been published in the American Journal of Sports Medicine.

CartiONE offers the same ACI treatment cell fresh chondrocyte bone marrow cell combination but:

  • a much shorter surgery time
  • can be used in clinical applications for larger cartilage lesions over 2sq cm
  • allow cell seeding on all regulatory approved chondral or osteochondral scaffolds
Further Information

For further information on Clinical Studies or on the technology please contact Orteq at

Dr Konrad Słynarski
Słynarski Knee Clinic
Warsaw, Poland 

Prof Peter Verdonk,
Orthoca Orthopedic Center
Antwerp, Belgium
 

Prof Martyn Snow
ROH
Birmingham, UK 

Prof Stefan Marlovits
Privatklinik Döbling
Vienna

Dr Emmanuel Papacostas
Aspeter Clinic Qatar

CartiONE Clinical Studies
Single-Stage Autologous Chondrocyte-Based Treatment for the Repair of Knee Cartilage Lesions
Two-Year Follow-up of a Prospective Single-Arm Multicenter Study

Konrad Słynarski, MD, PhD, Willem Cornelis de Jong, PhD, Martyn Snow, FRCS, Jeanine Anna Alphonse Hendriks, PhD, Clayton Ellis Wilson, PhD, and Peter Verdonk, MD, PhD.

Investigation performed at Ghent University Hospital, Ghent, Belgium; The Royal Orthopaedic Hospital NHS Foundation Trust, Birmingham, UK; The Center of Sports Medicine, Warsaw, Poland; AVIMED Hospital, Katowice, Poland; NSZOZ Endomedical, Poznan, Poland; and Dr Jan Biziel University Hospital No. 2, Bydgoszcz, Poland.

The first Instruct/CartiONE single-stage clinical study was recently published in the American Journal of Sports Medicine in April 2020.

The INSTRUCT for Repair of Knee Cartilage Defects Study (ClinicalTrials.gov, NCT01041885) was a prospective, single-arm, multicenter, multinational study conducted at 6 European sites in Belgium, the UK, and Poland. It included 40 patients with symptomatic knee cartilage lesions treated with freshly isolated autologous chondrocytes combined with bone marrow-derived cells and delivered in a biodegradable load-bearing scaffold.

The treatment is a cost-effective single-stage ACI alternative to the traditional two-stage autologous chondrocyte implantation (ACI) options.

Click here to see the CartiONE cell mix/Instruct publication in the AJSM.